IntraOp announces one for fifty reverse stock split

Sunnyvale, California; November 10, 2009 — IntraOp Medical Corporation
(OTCBB: IOPD) today announced that it has filed an amendment to its articles of incorporation to effect a reverse stock split, whereby each 50 shares of common stock was combined into one share of common stock. The outstanding share count after giving effect to the reverse split is now approximately 7.8 million shares, reduced from approximately 392.8 million shares. In addition, the company has reduced the number of authorized shares of common stock from 500 million to 100 million and authorized a class of up to 20 million shares of preferred stock for future fund raising rounds.

By effecting the reverse split and thereby reducing the company’s outstanding share count, IntraOp hopes to make the company’s stock more appealing to larger, institutional investors in its capital raising efforts.

“We have made significant progress this year towards our cost reduction and market development goals,” said John Powers, CEO of IntraOp Medical. “We are now in the phase where we need to raise a new round of capital to fully execute on our dermatology and IORT market strategies. This stock split enhances our ability to attract larger institutional investors and properly prepare for the future.”

IntraOp’s common stock began trading on a post-split basis on November 10, 2009. IntraOp’s ticker symbol has changed to IOPD.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.